Home › Companies › ARCUS BIOSCIENCES INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 5 items on ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024: 5 passed (calculated).
Significant dissent: 1 director (20.0% against).
Notable dissent: 2 directors (14.0%, 13.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ARCUS BIOSCIENCES INC. in the interactive database Compare manager voting policies
These tallies are ARCUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kathryn Falberg | 66,352,943 | -- | -- | 10,783,215 | 8,822,193 | 86% | Passed (calculated) | — |
| Elect Director: Linda Higgins | 61,694,808 | -- | -- | 15,441,350 | 8,822,193 | 80% | Passed (calculated) | — |
| Elect Director: Terry Rosen | 67,130,968 | -- | -- | 10,005,190 | 8,822,193 | 87% | Passed (calculated) | — |
| 2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 | 84,330,586 | 1,242,487 | 385,278 | -- | -- | 99% | Passed (calculated) | — |
| 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 74,230,276 | 2,863,260 | 42,662 | -- | 8,822,193 | 96% | Passed (calculated) | — |
Source: ARCUS BIOSCIENCES INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
216 asset managers disclosed a vote on at least one ARCUS BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Kathryn Falberg
ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kathryn Falberg”): 66,352,943 for, 10,783,215 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 20,673,016 for, 3,669,665 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,806,946 | 0 | 0 | 37,382 | For |
| BlackRock | 5,234,776 | 0 | 0 | 0 | For |
| Vanguard | 4,693,497 | 0 | 0 | 0 | For |
| State Street | 3,475,333 | 0 | 0 | 50,039 | For |
| Dimensional | 0 | 0 | 0 | 1,184,566 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 551,175 | Withhold |
| Charles Schwab | 468,738 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Equitable | 82,999 | 0 | 0 | 253,908 | Mixed |
| MUTUAL FUND SERIES TRUST | 240,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 175,280 | Withhold |
| Columbia Threadneedle | 155,787 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 139,727 | Withhold |
| Jackson National | 0 | 0 | 0 | 136,438 | Withhold |
| TIAA | 125,290 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 64,090 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 62,055 | Withhold |
| ProShares | 0 | 0 | 0 | 61,739 | Withhold |
| Principal | 0 | 0 | 0 | 60,715 | Withhold |
| Invesco | 58,086 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 57,898 | Withhold |
| Prudential/PGIM | 56,223 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 56,174 | Withhold |
| Lincoln Financial | 44,400 | 0 | 0 | 8,738 | Mixed |
| Thrivent | 0 | 0 | 0 | 46,429 | Withhold |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Linda Higgins, Ph.D.
ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Linda Higgins”): 61,694,808 for, 15,441,350 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 17,051,197 for, 7,291,484 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,806,946 | 0 | 0 | 37,382 | For |
| BlackRock | 5,234,776 | 0 | 0 | 0 | For |
| Vanguard | 4,693,497 | 0 | 0 | 0 | For |
| State Street | 35,943 | 0 | 0 | 3,489,429 | Withhold |
| Dimensional | 0 | 0 | 0 | 1,184,566 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 551,175 | Withhold |
| Charles Schwab | 468,738 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Equitable | 82,999 | 0 | 0 | 253,908 | Mixed |
| MUTUAL FUND SERIES TRUST | 240,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 175,280 | Withhold |
| Columbia Threadneedle | 155,787 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 139,727 | Withhold |
| Jackson National | 0 | 0 | 0 | 136,438 | Withhold |
| TIAA | 125,290 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 64,090 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 62,055 | Withhold |
| ProShares | 0 | 0 | 0 | 61,739 | Withhold |
| Principal | 0 | 0 | 0 | 60,715 | Withhold |
| Invesco | 0 | 0 | 0 | 58,086 | Withhold |
| American Century | 0 | 0 | 0 | 57,898 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 56,223 | Withhold |
| MFS | 0 | 0 | 0 | 56,174 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 53,138 | Withhold |
| Thrivent | 0 | 0 | 0 | 46,429 | Withhold |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Terry Rosen, Ph.D.
ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Terry Rosen”): 67,130,968 for, 10,005,190 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 21,500,622 for, 2,842,059 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,843,023 | 0 | 0 | 1,305 | For |
| BlackRock | 5,234,776 | 0 | 0 | 0 | For |
| Vanguard | 4,693,497 | 0 | 0 | 0 | For |
| State Street | 3,475,333 | 0 | 0 | 50,039 | For |
| Dimensional | 0 | 0 | 0 | 1,184,566 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 551,175 | 0 | 0 | 0 | For |
| Charles Schwab | 468,738 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Equitable | 336,907 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 240,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 175,280 | Withhold |
| Columbia Threadneedle | 155,787 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 139,727 | Withhold |
| Jackson National | 0 | 0 | 0 | 136,438 | Withhold |
| TIAA | 125,290 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 64,090 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 62,055 | Withhold |
| ProShares | 0 | 0 | 0 | 61,739 | Withhold |
| Principal | 0 | 0 | 0 | 60,715 | Withhold |
| Invesco | 58,086 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 57,898 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 56,223 | Withhold |
| MFS | 56,174 | 0 | 0 | 0 | For |
| Lincoln Financial | 44,400 | 0 | 0 | 8,738 | Mixed |
| Thrivent | 0 | 0 | 0 | 46,429 | Withhold |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 96.0% for (June 15, 2023 meeting) ▲ 0.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.
ARCUS BIOSCIENCES INC.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 74,230,276 for, 2,863,260 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,844,328 | 0 | 0 | 0 | For |
| BlackRock | 5,234,776 | 0 | 0 | 0 | For |
| Vanguard | 4,693,497 | 0 | 0 | 0 | For |
| State Street | 3,510,918 | 14,454 | 0 | 0 | For |
| Dimensional | 1,184,566 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 551,175 | 0 | 0 | 0 | For |
| Charles Schwab | 468,738 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Equitable | 336,907 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 240,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 175,280 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 155,787 | 0 | 0 | 0 | For |
| Victory Capital | 139,727 | 0 | 0 | 0 | For |
| Jackson National | 136,438 | 0 | 0 | 0 | For |
| TIAA | 125,290 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 64,090 | 0 | 0 | 0 | For |
| BNY Mellon | 62,055 | 0 | 0 | 0 | For |
| ProShares | 61,739 | 0 | 0 | 0 | For |
| Principal | 60,715 | 0 | 0 | 0 | For |
| Invesco | 0 | 58,086 | 0 | 0 | Against |
| American Century | 0 | 57,898 | 0 | 0 | Against |
| Prudential/PGIM | 56,223 | 0 | 0 | 0 | For |
| MFS | 0 | 56,174 | 0 | 0 | Against |
| Lincoln Financial | 53,138 | 0 | 0 | 0 | For |
| Thrivent | 46,429 | 0 | 0 | 0 | For |
Fund voting reports, all 77 managers: 23,981,570 for, 350,897 against, 10,214 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,708,631 | 0 | 0 | 0 | For |
| State Street | 4,484,507 | 30,622 | 0 | 0 | For |
| Woodline Partners LP | 2,498,994 | 0 | 0 | 0 | For |
| Point72 | 1,759,101 | 0 | 0 | 0 | For |
| BlackRock | 1,327,536 | 7,194 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,151,010 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,053,152 | 0 | 0 | 0 | For |
| AllianceBernstein | 990,799 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 957,299 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 869,790 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 732,497 | 0 | 0 | Against |
| Laurion Capital Management LP | 502,123 | 0 | 0 | 0 | For |
| Charles Schwab | 493,823 | 0 | 0 | 0 | For |
| Northern Trust | 415,764 | 2,016 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 379,100 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 288,392 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 283,746 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 259,372 | 0 | 0 | Against |
| UBS | 19 | 233,242 | 0 | 0 | Against |
| DAFNA Capital Management LLC | 231,715 | 0 | 0 | 0 | For |
| Two Sigma | 223,044 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 213,023 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 204,398 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 179,675 | 0 | 0 | 0 | For |
| Dimensional | 176,538 | 0 | 0 | 0 | For |
Institutional-manager reports, all 162 managers: 25,065,027 for, 2,033,215 against, 175 abstained, 2,930 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 98.3% for (June 15, 2023 meeting) ▲ 0.2 pts
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.
ARCUS BIOSCIENCES INC.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 84,330,586 for, 1,242,487 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 23,785,827 for, 546,640 against, 10,214 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,844,328 | 0 | 0 | 0 | For |
| BlackRock | 5,234,776 | 0 | 0 | 0 | For |
| Vanguard | 4,693,497 | 0 | 0 | 0 | For |
| State Street | 3,520,086 | 5,286 | 0 | 0 | For |
| Dimensional | 1,184,566 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 551,175 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 468,738 | 0 | 0 | Against |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Equitable | 336,907 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 240,000 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 175,280 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 155,787 | 0 | 0 | 0 | For |
| Victory Capital | 139,727 | 0 | 0 | 0 | For |
| Jackson National | 136,438 | 0 | 0 | 0 | For |
| TIAA | 125,290 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 64,090 | 0 | 0 | 0 | For |
| BNY Mellon | 62,055 | 0 | 0 | 0 | For |
| ProShares | 61,739 | 0 | 0 | 0 | For |
| Principal | 60,715 | 0 | 0 | 0 | For |
| Invesco | 58,086 | 0 | 0 | 0 | For |
| American Century | 57,898 | 0 | 0 | 0 | For |
| Prudential/PGIM | 56,223 | 0 | 0 | 0 | For |
| MFS | 56,174 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,138 | 0 | 0 | 0 | For |
| Thrivent | 46,429 | 0 | 0 | 0 | For |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 90,900,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 6.43% |
| 2 | BlackRock | 5.76% |
| 3 | Vanguard | 5.16% |
| 4 | State Street | 3.88% |
| 5 | Dimensional | 1.30% |
| 6 | AB DISCOVERY GROWTH FUND, INC. | 0.61% |
| 7 | Charles Schwab | 0.52% |
| 8 | Delaware/Macquarie | 0.42% |
| 9 | Equitable | 0.37% |
| 10 | MUTUAL FUND SERIES TRUST | 0.26% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.18% |
| 2 | State Street | 4.97% |
| 3 | Woodline Partners LP | 2.75% |
| 4 | Point72 | 1.94% |
| 5 | BlackRock | 1.47% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.27% |
| 7 | AMERIPRISE FINANCIAL INC | 1.16% |
| 8 | AllianceBernstein | 1.09% |
| 9 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.05% |
| 10 | Decheng Capital LLC | 0.96% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Gilead Sciences, Inc. | 30,061,124 | 33.07% | Proxy statement (DEF 14A), table as of March 1, 2024 |
| BlackRock, Inc. | 10,035,170 | 11.04% | Proxy statement (DEF 14A), table as of March 1, 2024 |
| Vanguard Group | 6,629,453 | 7.29% | Form 13F, quarter ended March 31, 2024 |
| State Street | 4,904,513 | 5.40% | Form 13F, quarter ended March 31, 2024 |
| FMR LLC | 4,728,782 | 5.20% | Proxy statement (DEF 14A), table as of March 1, 2024 |
| Terry Rosen, Ph.D. | 3,790,875 | 4.17% | Schedule 13D, filed December 17, 2024 |
| Point72 | 1,914,932 | 2.11% | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 1,621,409 | 1.78% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,536,088 | 1.69% | Form 13F, quarter ended March 31, 2024 |
| Juan Carlos Jaen, Ph.D. | 1,421,141 | 1.56% | Proxy statement (DEF 14A), table as of March 1, 2024 |
Percentages above are of 90,900,000 shares outstanding, as reported by ARCUS BIOSCIENCES INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ARCUS BIOSCIENCES INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 216 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,453 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUS BIOSCIENCES INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ARCUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ARCUS BIOSCIENCES (RCUS) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.